Pacira BioSciences
PCRX
242 hedge funds and large institutions have $986M invested in Pacira BioSciences in 2026 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 91 increasing their positions, 83 reducing their positions, and 43 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
61% more call options, than puts
Call options by funds: $477K | Put options by funds: $296K
10% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 83
1.4% less ownership
Funds ownership: 109.11% → 107.71% (-1.4%)
7% less funds holding
Funds holding: 260 → 242 (-18)
19% less capital invested
Capital invested by funds: $1.21B → $986M (-$229M)
30% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 43
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EF
Empowered Funds
Havertown,
Pennsylvania
|
+$6.15M |
| 2 |
Goldman Sachs
New York
|
+$5.99M |
| 3 |
Morgan Stanley
New York
|
+$4.44M |
| 4 |
LSV Asset Management
Chicago,
Illinois
|
+$4.38M |
| 5 |
BCC
Bridge City Capital
Lake Oswego,
Oregon
|
+$2.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$18.7M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$11.3M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
-$11.1M |
| 4 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$7.86M |
| 5 |
JGC
J. Goldman & Co
New York
|
-$7.54M |
PCRX Hedge Fund Activity: Q1 2026 in Review
242 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q1 2026, worth a combined $986M — down 19% from $1.21B a quarter earlier.
Sellers outnumbered buyers: 43 funds closed out of PCRX and 30 opened new positions — a net loss of 13 holders — while 83 trimmed existing stakes and 91 added.
The largest buyer was Empowered Funds, opening a new position worth an estimated $6.15M. The largest seller was Balyasny Asset Management, cutting an estimated $18.7M.
- 242 institutional investors held Pacira BioSciences (PCRX) as of Q1 2026, down from 260 in Q4 2025.
- Funds reported $986M of Pacira BioSciences stock for Q1 2026, down 19% quarter-over-quarter.
- 30 funds opened new Pacira BioSciences positions in Q1 2026 and 43 closed out, a net change of -13 holders.
- The largest Pacira BioSciences buyer in Q1 2026 was Empowered Funds, an estimated $6.15M added.
- The largest Pacira BioSciences seller in Q1 2026 was Balyasny Asset Management, an estimated $18.7M sold.
Based on aggregated 13F filings for Q1 2026.